Read More Pharma Industry News Dimerix (ASX: DXB) acquires Phase 2-ready DMX-652 as acute kidney injury deal reshapes renal pipeline Dimerix has acquired a Phase 2-ready acute kidney injury candidate with an open United States clinical application, giving the biotechnology company a nearer-term catalyst beyond its long-running ACTION3 programme. bySrinathJuly 17, 2026